HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Onconova Therapeutics (NASDAQ:ONTX) and maintained a price target of $11.
October 12, 2023 | 2:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Onconova Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $11.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Onconova Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100